Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction

In the article by AbouEzzeddine et al “Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction,” which published on February 18, 2017, and appeared in the February 2017 issue of the journal *J Am Heart Assoc.* 2017;6:e004382. DOI: 10.1161/JAHA.116.004382.), the authors mistakenly referred to the ST2 as Suppression of Tumorigenicity 2, an entirely unrelated gene. The gene that is commonly reported as being a biomarker that is upregulated in heart failure and other systemic inflammatory diseases (and that the authors intended to refer to in this manuscript) is the gene IL1RL1 (interleukin 1 receptor like 1). Ambiguously, this was originally also termed ST2; hence the error that has been commonly made in the literature. The article has been corrected and all reference to Suppression of Tumorigenicity 2 has been corrected to Soluble ST2.

The authors regret the error.

The online version of the article has been updated and is available at http://jaha.ahajournals.org/content/6/2/e004382
Suppression of Tumorigenicity 2 in Heart Failure With Preserved Ejection Fraction

*J Am Heart Assoc.* 2017;6:e002231; originally published September 20, 2017;
doi: 10.1161/JAHA.117.002231

The *Journal of the American Heart Association* is published by the American Heart Association, 7272 Greenville Avenue, Dallas, TX 75231
Online ISSN: 2047-9980

The online version of this article, along with updated information and services, is located on the World Wide Web at:
http://jaha.ahajournals.org/content/6/9/e002231